Evidence map›Paper›PMID 29402287›Full record

ArticleCell communication and signaling : CCS2018

Oxidative phosphorylation activation is an important characteristic of DOX resistance in hepatocellular carcinoma cells.

Li Wu, Jiayu Zhao, Kexin Cao, Xiao Liu, Hao Cai, Jiaqi Wang, Weidong Li, Zhipeng Chen

Open access · goldAbstract read
In one paragraph

Article in Cell communication and signaling : CCS, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.8field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Li WuDepartment of Pharmacology, School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, People's Republic of China. wuli@njucm.edu.cn.ORCID 0000-0001-9380-8620
Jiayu ZhaoDepartment of Pharmacology, School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, People's Republic of China.
Kexin CaoDepartment of Pharmacology, School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, People's Republic of China.
Xiao LiuDepartment of Pharmacology, School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, People's Republic of China.
Hao CaiDepartment of Pharmacology, School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, People's Republic of China.
Jiaqi WangDepartment of Pharmacology, School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, People's Republic of China.
Weidong LiDepartment of Pharmacology, School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, People's Republic of China.
Zhipeng ChenDepartment of Pharmacology, School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, People's Republic of China. czpcpu2000@hotmail.com.
Nanjing University of Chinese Medicine · CN

Funding

National Natural Science Foundation of China 81473147National Natural Science Foundation of China 81503308National Natural Science Foundation of China 81673600Open Project Program of Jiangsu Key Laboratory for Pharmacology and Safety Evaluation of Chinese Materia Medica, Nanjing University of Chinese Medicine JKLPSE201608Postgraduate Research Innovation Project of Jiangsu Higher Education Institutions KYLX16_1160Project Funded by the Priority Academic Program Development of Jiangsu Higher Education Institutions PAPDProject of Administration of Traditional Chinese Medicine of Jiangsu Province YB2015007Top-notch Academic Programs Project of Jiangsu Higher Education Institutions PPZY2015A070Top-notch Academic Programs Project of Jiangsu Higher Education Institutions TAPP
6 · The paper itself

Abstract

backgroundDespite the implications for tumor growth and cancer drug resistance, the mechanisms underlying differences in energy metabolism among cells remain unclear.

methodsTo analyze differences between cell types, cell viability, ATP and α-ketoglutaric acid levels, the oxygen consumption rate and extracellular acidification rate, and the expression of key enzymes involved in α-KG metabolism and transfer were examined. Additionally, UPLC-MS/MS was used to determine the doxorubicin (DOX) content in SMMC-7721 and SMMC-7721/DOX cells.

resultsWe found that energy metabolism in SMMC-7721 cells is mainly dependent on the glycolysis pathway, whereas SMMC-7721/DOX cells depend more heavily on the oxidative phosphorylation pathway. Cell viability and intracellular ATP levels in SMMC-7721/DOX cells were significantly reduced by rotenone and oligomycin, inhibitors of oxidative phosphorylation. However, SMMC-7721 cell properties were more strongly influenced by an inhibitor of glycolysis, 2-deoxy-D-glucose. Furthermore, the suppressive effect of α-KG on ATP synthase plays an important role in the low levels of oxidative phosphorylation in SMMC-7721 cells; this effect could be strengthened by the metabolic poison methotrexate and reversed by L-(-)-malic acid, an accelerator of the malate-aspartate cycle.

conclusionsThe inhibitory effect of α-KG on ATP synthase was uncoupled with the tricarboxylic acid cycle and oxidative phosphorylation in SMMC-7721 cells; accordingly, energy metabolism was mainly determined by glycolysis. In drug-resistant cells, a remarkable reduction in the inhibitory effects of α-KG on ATP synthase resulted in better coordination among the TCA cycle, oxidative phosphorylation, and glycolysis, providing novel potential strategies for clinical treatment of liver cancer resistance.

Indexed as

Drug Resistance, NeoplasmAdenosine TriphosphateATP Synthetase ComplexesCarcinoma, HepatocellularCell Line, TumorCell SurvivalDeoxyglucoseDoxorubicinEnergy MetabolismGlycolysisHumansKetone OxidoreductasesLiver NeoplasmsMalatesMethotrexateOxidative Phosphorylation2-oxoglutarate synthaseAdenosine TriphosphateATP Synthetase ComplexesDeoxyglucoseDoxorubicinKetone OxidoreductasesMalatesmalic acidMethotrexateDrug resistanceEnergy metabolismHepatocellular carcinomaMechanismα-ketoglutaric acid

Identifiers

PMID29402287
PMCPMC5799923
OpenAlexW2797797187

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.